Adicet Bio

Nanoscope Therapeutics plans to file a BLA for MCO-010 to treat retinitis pigmentosa. Seven patients treated with bluebird bio's eli-cel developed hematologic malignancies. Poseida Therapeutics' P-BCMA-ALLO1 showed a 91% ORR in r/r multiple myeloma. Kiromic BioPharma's KB-GDT-01 provided disease stabilization in NSCLC. Adicet Bio's ADI-100 received FDA clearance for additional patient recruitment in lupus nephritis trial. ElevateBio's LNP platform successfully edited liver genes in mice with low immunogenicity.

Adicet Bio expands ADI-001 clinical program to include idiopathic inflammatory myopathy and stiff person syndrome, with patient enrollment expected in Q1 2025. Initial Phase 1 data for multiple autoimmune diseases planned for first half of 2025.

In September 2024, CGTLive tracked promising data updates in CAR-T therapy for DLBCL, gene therapy for XLRP, and more. REGENXBIO's RGX-121 showed efficacy in MPSII, Biogen's nusinersen demonstrated efficacy in SMA at a higher dose, Allogeneic CAR-T azer-cel achieved CRs in DLBCL, Beacon's AGTC-501 maintained a favorable benefit-risk profile in XLRP, and Adicet Bio's ADI-001 indicated potential for autoimmune disease treatment.

Adicet Bio's ADI-001, a CAR-engineered gamma delta T-cell therapy, shows robust tissue trafficking and complete B-cell depletion in secondary lymphoid tissue, supporting its potential for autoimmune disease treatment. The company plans to focus on ADI-001 for lupus nephritis, systemic lupus erythematosus, systemic sclerosis, and antineutrophil cytoplasmic autoantibody-associated vasculitis, with clinical trial enrollment expected before 2024 ends.

DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech and Merck. Promising drugs like Atezolizumab and ADI-270 are under various clinical trial phases, with recent FDA Fast Track designations for ADI-270 in metastatic RCC.

DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech, Allogene Therapeutics, and Merck & Co. Inc. Promising therapies such as Atezolizumab and ALLO-316 are under various clinical trial phases, with recent FDA Fast Track designations and IND approvals for novel drugs like ADI-270 and AB-2100.

Mantle cell lymphoma (MCL) treatment outcomes improve with novel targeted therapies like BTK inhibitors. DelveInsight's 'Mantle Cell Lymphoma Pipeline Insight 2024' covers 20+ companies developing 22+ therapies, including Venetoclax and ADI-001. Key events include AstraZeneca's Phase III ECHO trial and BeiGene's AACR presentation.